Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity
J Domachowske, SA Madhi, EAF Sim�es…�- …�England Journal of�…, 2022 - Mass Medical Soc
New England Journal of Medicine, 2022•Mass Medical Soc
Nirsevimab for Prevention of RSV Nirsevimab is a monoclonal antibody targeting respiratory
syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to
receive palivizumab, including those born preterm (at 35 weeks of gestation or less) and
those with congenital heart disease or chronic lung disease of prematurity. No safety
concerns were identified.
syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to
receive palivizumab, including those born preterm (at 35 weeks of gestation or less) and
those with congenital heart disease or chronic lung disease of prematurity. No safety
concerns were identified.
Nirsevimab for Prevention of RSV
Nirsevimab is a monoclonal antibody targeting respiratory syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to receive palivizumab, including those born preterm (at 35 weeks of gestation or less) and those with congenital heart disease or chronic lung disease of prematurity. No safety concerns were identified.
The New England Journal Of Medicine